Tested Applications
| Positive FC detected in | human PBMCs |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
98260-1-RR targets EMR2/CD312 in FC applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | Recombinant protein Predict reactive species |
| Full Name | egf-like module containing, mucin-like, hormone receptor-like 2 |
| Calculated Molecular Weight | 90 kDa |
| GenBank Accession Number | NM_013447.3 |
| Gene Symbol | EMR2 |
| Gene ID (NCBI) | 30817 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purfication |
| UNIPROT ID | Q9UHX3-1 |
| Storage Buffer | PBS with 0.09% sodium azide , pH 7.3 |
| Storage Conditions | Store at 2 - 8°C. Stable for one year after shipment. |
Background Information
EMR2 (Epidermal Growth Factor-like module-containing Mucin-like Hormone Receptor 2), also known as CD312 or ADGRE2, is a member of the adhesion-GPCR family that contains extracellular EGF-like domains. EMR2 contains a total of five tandem EGF-like domains and expresses similar protein isoforms consisting of various numbers of EGF-like domains as a result of alternative RNA splicing (PMID: 10903844). EMR2 is restricted to myeloid cells including monocytes, macrophages, dendritic cells and granulocytes28 and its expression is highly regulated during monocyte/macrophage differentiation (PMID: 31969668).The ligation of EMR2 could increase neutrophil adhesion, migration and anti-microbial mediator production and could enhance the systemic inflammation (PMID: 27905560).
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for EMR2/CD312 antibody 98260-1-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
